- Home
- IMPP vs BDTX Comparison
IMPP vs BDTX Comparison
Compare IMPP & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | BDTX |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.6M | 126.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMPP | BDTX |
|---|---|---|
| Price | $3.59 | $2.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.50 | ★ $10.40 |
| AVG Volume (30 Days) | 729.2K | ★ 818.6K |
| Earning Date | 02-13-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | 0.38 |
| Revenue | ★ $136,071,654.00 | $70,000,000.00 |
| Revenue This Year | $7.55 | N/A |
| Revenue Next Year | $52.61 | N/A |
| P/E Ratio | ★ $3.58 | $5.87 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.12 | $1.20 |
| 52 Week High | $6.57 | $4.94 |
Technical Indicators
Market Signals| Indicator | IMPP | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 38.03 |
| Support Level | $3.15 | $2.13 |
| Resistance Level | $3.78 | $2.30 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 53.05 | 18.42 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.